Portola Pharmaceuticals Stock Rating Upgraded by Zacks (PTLA)
Portola Pharmaceuticals (NASDAQ:PTLA) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a research report issued on Tuesday. The firm currently has a $28.30 target price on the stock. Zacks‘s price target would indicate a potential upside of 7.77% from the company’s current price.
Shares of Portola Pharmaceuticals (NASDAQ:PTLA) traded down 0.69% during mid-day trading on Tuesday, hitting $26.08. The stock had a trading volume of 100,188 shares. Portola Pharmaceuticals has a one year low of $19.59 and a one year high of $31.48. The stock has a 50-day moving average of $26.39 and a 200-day moving average of $25.24. The company’s market cap is $1.080 billion.
Portola Pharmaceuticals (NASDAQ:PTLA) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.76) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.79) by $0.03. The company had revenue of $2.42 billion for the quarter, compared to the consensus estimate of $2.44 million. Portola Pharmaceuticals’s revenue was down 7.2% compared to the same quarter last year. Analysts expect that Portola Pharmaceuticals will post $-3.45 EPS for the current fiscal year.
Portola Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who has limited or no approved treatment options.
To view Zacks’ full report, visit Zacks’ official website.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.